These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9357529)

  • 21. Synthesis and cannabinoid receptor binding activity of conjugated triene anandamide, a novel eicosanoid.
    Wise ML; Soderstrom K; Murray TF; Gerwick WH
    Experientia; 1996 Jan; 52(1):88-92. PubMed ID: 8575565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore.
    Thomas BF; Adams IB; Mascarella SW; Martin BR; Razdan RK
    J Med Chem; 1996 Jan; 39(2):471-9. PubMed ID: 8558515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity relationships of anandamide, an endogenous cannabinoid ligand.
    Khanolkar AD; Makriyannis A
    Life Sci; 1999; 65(6-7):607-16. PubMed ID: 10462061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
    Calignano A; La Rana G; Makriyannis A; Lin SY; Beltramo M; Piomelli D
    Eur J Pharmacol; 1997 Dec; 340(2-3):R7-8. PubMed ID: 9537804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
    Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
    Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, cannabinoid receptor activity, and enzymatic stability of reversed amide derivatives of arachidonoyl ethanolamide.
    Parkkari T; Savinainen JR; Raitio KH; Saario SM; Matilainen L; Sirviö T; Laitinen JT; Nevalainen T; Niemi R; Järvinen T
    Bioorg Med Chem; 2006 Aug; 14(15):5252-8. PubMed ID: 16644227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups.
    Berglund BA; Boring DL; Wilken GH; Makriyannis A; Howlett AC; Lin S
    Prostaglandins Leukot Essent Fatty Acids; 1998 Aug; 59(2):111-8. PubMed ID: 9774174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.
    Fride E; Mechoulam R
    Eur J Pharmacol; 1993 Feb; 231(2):313-4. PubMed ID: 8384116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discriminative stimulus effects of anandamide in rats.
    Wiley J; Balster R; Martin B
    Eur J Pharmacol; 1995 Mar; 276(1-2):49-54. PubMed ID: 7781695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase.
    Vogel Z; Barg J; Levy R; Saya D; Heldman E; Mechoulam R
    J Neurochem; 1993 Jul; 61(1):352-5. PubMed ID: 8515284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories.
    Barnett-Norris J; Guarnieri F; Hurst DP; Reggio PH
    J Med Chem; 1998 Nov; 41(24):4861-72. PubMed ID: 9822555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear magnetic resonance for studying recognition processes between anandamide and cannabinoid receptors.
    Bonechi C; Martini S; Brizzi V; Brizzi A; Massarelli P; Bruni G; Rossi C
    Eur J Med Chem; 2006 Oct; 41(10):1117-23. PubMed ID: 16837109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors.
    Ueda N; Goparaju SK; Katayama K; Kurahashi Y; Suzuki H; Yamamoto S
    J Med Invest; 1998 Aug; 45(1-4):27-36. PubMed ID: 9864962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
    Welch SP; Huffman JW; Lowe J
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors.
    Boring DL; Berglund BA; Howlett AC
    Prostaglandins Leukot Essent Fatty Acids; 1996 Sep; 55(3):207-10. PubMed ID: 8931121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.
    Deutsch DG; Lin S; Hill WA; Morse KL; Salehani D; Arreaza G; Omeir RL; Makriyannis A
    Biochem Biophys Res Commun; 1997 Feb; 231(1):217-21. PubMed ID: 9070252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
    Sheskin T; Hanus L; Slager J; Vogel Z; Mechoulam R
    J Med Chem; 1997 Feb; 40(5):659-67. PubMed ID: 9057852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors.
    Edgemond WS; Campbell WB; Hillard CJ
    Prostaglandins Leukot Essent Fatty Acids; 1995; 52(2-3):83-6. PubMed ID: 7784462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.
    López-Rodríguez ML; Viso A; Ortega-Gutiérrez S; Lastres-Becker I; González S; Fernández-Ruiz J; Ramos JA
    J Med Chem; 2001 Dec; 44(26):4505-8. PubMed ID: 11741470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anandamides inhibit binding to the muscarinic acetylcholine receptor.
    Lagalwar S; Bordayo EZ; Hoffmann KL; Fawcett JR; Frey WH
    J Mol Neurosci; 1999; 13(1-2):55-61. PubMed ID: 10691292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.